iBio
IBIO
70 hedge funds and large institutions have $17.5M invested in iBio in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 33 reducing their positions, and 12 closing their positions.
15% more call options, than puts
Call options by funds: $260K | Put options by funds: $226K
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
9% less funds holding
Funds holding: 77 → 70 (-7)
30% less capital invested
Capital invested by funds: $25M → $17.5M (-$7.53M)
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
61% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$182K |
| 2 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$41.8K |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$35.4K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$22.6K |
| 5 |
US Bancorp
Minneapolis,
Minnesota
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$560K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$390K |
| 3 |
AGM
Alpine Global Management
New York
|
-$124K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$120K |
| 5 |
Man Group
London,
United Kingdom
|
-$114K |
IBIO Hedge Fund Activity: Q1 2022 in Review
70 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q1 2022, worth a combined $17.5M — down 30% from $25M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of IBIO and 5 opened new positions — a net loss of 7 holders — while 33 trimmed existing stakes and 13 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $182K. The largest seller was Vanguard Group, cutting an estimated $560K.
- 70 institutional investors held iBio (IBIO) as of Q1 2022, down from 77 in Q4 2021.
- Funds reported $17.5M of iBio stock for Q1 2022, down 30% quarter-over-quarter.
- 5 funds opened new iBio positions in Q1 2022 and 12 closed out, a net change of -7 holders.
- The largest iBio buyer in Q1 2022 was Renaissance Technologies, an estimated $182K added.
- The largest iBio seller in Q1 2022 was Vanguard Group, an estimated $560K sold.
Based on aggregated 13F filings for Q1 2022.